MX2021012852A - Metodo para preparar formulaciones de peptidos estables. - Google Patents

Metodo para preparar formulaciones de peptidos estables.

Info

Publication number
MX2021012852A
MX2021012852A MX2021012852A MX2021012852A MX2021012852A MX 2021012852 A MX2021012852 A MX 2021012852A MX 2021012852 A MX2021012852 A MX 2021012852A MX 2021012852 A MX2021012852 A MX 2021012852A MX 2021012852 A MX2021012852 A MX 2021012852A
Authority
MX
Mexico
Prior art keywords
preparing stable
peptide formulations
stable peptide
preparing
powder formulation
Prior art date
Application number
MX2021012852A
Other languages
English (en)
Inventor
Gregory Nelson Brown
Scoik Kurt Gard Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021012852A publication Critical patent/MX2021012852A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un método mejorado para preparar una formulación en polvo que contiene un péptido. La presente invención también proporciona un método mejorado para preparar una formulación en polvo que contiene glucagón o un análogo de glucagón, en donde dicha formulación en polvo es adecuada para administración nasal.
MX2021012852A 2019-04-26 2020-04-20 Metodo para preparar formulaciones de peptidos estables. MX2021012852A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839246P 2019-04-26 2019-04-26
PCT/US2020/028988 WO2020219391A1 (en) 2019-04-26 2020-04-20 Method for preparing stable peptide formulations

Publications (1)

Publication Number Publication Date
MX2021012852A true MX2021012852A (es) 2021-12-10

Family

ID=70554273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012852A MX2021012852A (es) 2019-04-26 2020-04-20 Metodo para preparar formulaciones de peptidos estables.

Country Status (20)

Country Link
US (1) US20220192988A1 (es)
EP (1) EP3958838A1 (es)
JP (2) JP7245926B2 (es)
KR (1) KR20210143253A (es)
CN (1) CN113727700A (es)
AR (1) AR118690A1 (es)
AU (1) AU2020261941B2 (es)
BR (1) BR112021018325A2 (es)
CA (1) CA3134757A1 (es)
CL (1) CL2021002690A1 (es)
CO (1) CO2021014034A2 (es)
EA (1) EA202192475A1 (es)
EC (1) ECSP21079422A (es)
IL (1) IL286426A (es)
MA (1) MA55757A (es)
MX (1) MX2021012852A (es)
PE (1) PE20212368A1 (es)
SG (1) SG11202110413YA (es)
TW (1) TWI771669B (es)
WO (1) WO2020219391A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116718762A (zh) * 2023-06-09 2023-09-08 上海品峰医疗科技有限公司 一种多肽类样本稳定剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
AU2003212912A1 (en) * 2002-02-04 2003-09-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
KR101593406B1 (ko) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 글루카곤 유사체
SG172170A1 (en) 2008-12-15 2011-07-28 Zealand Pharma As Glucagon analogues
EP2454282B1 (en) 2009-07-13 2015-03-04 Zealand Pharma A/S Acylated glucagon analogues
EP2552952A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
CA2839867A1 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2793931A2 (en) 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon analogues
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9018162B2 (en) * 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP3673899A1 (en) 2015-02-17 2020-07-01 Eli Lilly And Co. Nasal powder formulation for treatment of hypoglycemia

Also Published As

Publication number Publication date
CO2021014034A2 (es) 2021-10-29
AU2020261941B2 (en) 2023-04-06
EA202192475A1 (ru) 2022-01-28
JP7245926B2 (ja) 2023-03-24
CN113727700A (zh) 2021-11-30
US20220192988A1 (en) 2022-06-23
SG11202110413YA (en) 2021-10-28
MA55757A (fr) 2022-03-02
AR118690A1 (es) 2021-10-27
CL2021002690A1 (es) 2022-07-08
JP2023075249A (ja) 2023-05-30
BR112021018325A2 (pt) 2021-11-23
IL286426A (en) 2021-10-31
KR20210143253A (ko) 2021-11-26
AU2020261941A1 (en) 2021-10-14
PE20212368A1 (es) 2021-12-21
EP3958838A1 (en) 2022-03-02
WO2020219391A1 (en) 2020-10-29
JP2022529614A (ja) 2022-06-23
ECSP21079422A (es) 2021-11-30
TWI771669B (zh) 2022-07-21
CA3134757A1 (en) 2020-10-29
TW202108599A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
MX2021009475A (es) Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
PH12017501486A1 (en) Nasal powder formulation for treatment of hypoglycemia
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2021006969A (es) Ligante peptidico.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2018016424A (es) Formulaciones de deposito.
MX2022003633A (es) Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
MX2020008076A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2021012852A (es) Metodo para preparar formulaciones de peptidos estables.
AU2017370226A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
MX2019011639A (es) Formulacion farmaceutica.
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
IL291283A (en) Formulations for drug delivery
MX2020010928A (es) Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea.
MX2021015930A (es) Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1.
ZA202200282B (en) Solid dose formulations for needle-free delivery
WO2020070620A3 (en) Formulation and aerosol canisters, inhalers, and the like containing the formulation
MX2020011170A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona.
TW202426448A (zh) 醫藥化合物、其鹽類、其製劑及其等之製備和使用之方法